<?xml version="1.0" encoding="UTF-8"?>
<p id="p0165">
 <italic>PiCoVacc</italic> from Sinovac Biotech is an inactivated virus vaccine and is undergoing parallel phase I-II trials planned on 144 volunteers. Sinovac has partnered with US-based Dynavax. The vaccine produced neutralizing antibodies in mice, rats, and rhesus monkey which are protective in challenge experiments (
 <xref rid="bib47" ref-type="bibr">47</xref>, 
 <xref rid="bib76" ref-type="bibr">76</xref>).
</p>
